Table of Contents
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):January 31, 2003
Biogen, Inc.
Massachusetts | 0-12042 | 04-3002117 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Fourteen Cambridge Center
Cambridge, Massachusetts 02142
(Address of Principal Executive Offices)
(617) 679-2000
(Registrant’s telephone number, including area code)
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE. | ||||||||
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. | ||||||||
SIGNATURES | ||||||||
EXHIBIT INDEX | ||||||||
EX-99.1 Press Release Dated January 31, 2003 |
Table of Contents
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
On January 31, 2003, the Registrant publicly disseminated a press release announcing the approval of AMEVIVE® (alefacept) for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibit.
99.1 The Registrant’s Press Release dated January 31, 2003.
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIOGEN, INC | ||
By: /s/ Anne Marie Cook | ||
Anne Marie Cook Vice President, Chief Corporate Counsel | ||
Dated: January 31, 2003 |
Table of Contents
EXHIBIT INDEX
Exhibit Number | Description | |
99.1 | The Registrant’s Press Release dated January 31, 2003 |